-
Analysis of Receptor Tyrosine Kinase Internalization Using Flow Cytometry
Time of Update: 2021-02-27
To understand how cMet signaling for normal cell growth is controlled by endocytosis and how these mechanisms are dysregulated in metastatic cancers, we developed flow cytometry-based assays to examine cMet internalization.
-
Lancet: Compared to the efficacy of three MET kinase inhibitors for metastatic pap-shaped renal cell carcinoma
Time of Update: 2021-02-26
, metastasis PRCC patients received significantly longer PFS after treatment with cabotinib than Schoini.
-
The study revealed the mechanism by which PDK1, a protein kinase, regulates Tfh cell differentiation
Time of Update: 2021-02-23
/> this paper, based on PY3K downstream protein kinase PDK1 (serine/threonine kinase 3-phosphoinositide-dependent kin proteinase 1) condition knockout mice, combined with a variety of genetically engineered mouse models of the immune response analysis
-
Pfizer announces that the second generation of EGFR-Tyrosine kinase inhibitors has landed in China
Time of Update: 2021-02-22
with late-stage EGFR mutation. Recently, Pfizer announced that the second generation of EGFR-Tyrosine kinase inhibitor (TKI) targeted drug dacotinib (commodity name: Dozerrun ®) has officially landed in China, and launched
-
Science: Reveals dynamic compositional changes in ABL kinases
Time of Update: 2021-02-22
in a new study, researchers at St. Jude Children's Research Hospital in the United States visualized the structure of previously unknown ABL kinases, providing new insights into the design of targeted therapies for adult and child cancer patients.
-
Researchers have developed a third-generation new FLT3 kinase inhibition for the selective mutation of FLT3-ITD for acute myeloid leukemia.
Time of Update: 2021-02-17
In this work, the researchers developed a new FLT3-ITD mutation-selective type II kinase inhibitor CHMFL-FLT3-335, starting with the structure of the nonse specific FLT3 inhibitor AZD2932 and sorafinib (type II multi-target kinase inhibitor).
-
Locally adhered plaque kinase proteins are associated with chemotherapy resistance to ovarian cancer
Time of Update: 2021-02-15
"There are a number of drugs that are being tested in early clinical trials, including at the University of California, San Diego Health Center, which inhibits locally adhesive plaque kinases," Stupack said.
-
The risk of progression of thyroid cancer disease was reduced by 78% in phase 3 clinical trials of poly kinase inhibitors
Time of Update: 2021-02-11
In a critical Phase 3 clinical trial called COSMIC-311, randomized double-blind, placebo-containing control, about 300 patients with radioactive iodine incurable differentiated thyroid cancer were treated with Cabometyx or a placebo.
-
The powerful FGFR kinase inhibitor Pemazyre EU is about to be approved for the introduction of Xinda Bio to China
Time of Update: 2021-02-04
In April 2020, the FDA approved Pemazyre for the treatment of patients with locally advanced or metastatic bile tube cancer who had previously received treatment, had FGFR2 fusion or rearm, and could not be surgically removed.
-
Br J Cancer: Comparative analysis of three tyrosine kinase inhibitors targeted at HER2
Time of Update: 2021-02-03
previous studies have confirmed gene amplification of HER2 and over-expression of proteins in breast and other cancers, and many her2-targeted therapies have been developed and approved.
-
Natto kinase was first approved as an efficacy ingredient
Time of Update: 2021-02-02
" natto kinase as an efficacy component to obtain state-level approval, not only to promote China's natto industry to the track of standardized development, but also to promote China's natto industry to a new level of development.
-
Measuring In Vivo Signaling Kinetics in a Mitogen-Activated Kinase Pathway Using Dynamic Input Stimulation
Time of Update: 2021-02-01
We can measure a property we termed pathway bandwidth to putin vivo bounds on the kinetics of the mitogen-activated protein kinase (MAPk) signaling cascade inSaccharomyces cerevisiae that responds to hyperosmotic stress [the High Osmolarity Glycerol (HOG) pathway].
-
Mitogen-Activated Protein Kinase Pathways in Interferon Signaling
Time of Update: 2021-01-25
There is recent evidence that in addition to the classic JAK/STAT pathways, mitogen-activated proteins (MAP) kinase pathways play important roles in Type I interferon signaling and the generation of interferon responses.
-
Domestic kinase inhibitors enter the international market! And yellow medicine Sovantini
Time of Update: 2021-01-21
And Huang China Pharmaceutical Technology Co., Ltd. ("and Yellow Pharma" or "Chi-Med") recently announced that it has begun rolling the submission to the U.S. Food and Drug Administration (FDA) of the first part of the new drug listing application
-
Domestic kinase inhibitors! And yellow medicine Sofantini (Sutaida®) approved by the State Drug
Time of Update: 2021-01-20
("and Huang Medicine" or "Chi-Med") recently announced that Sovantini (Chinese trade name: Sutaida ®) has been officially approved by China's State Drug Administration (NMPA) for the treatment of non-pancreatic neuroendocrine tumors (NET).
-
The first domestic research and development of a new generation of NTRK/ROS1 multi-kinase inhibitor project completed phase I clinical first subjects
Time of Update: 2021-01-19
The first domestic research and development of a new generation of NTRK/ROS1 multi-kinase inhibitor SIM1803-1A tablets in China on January 5, 2021 completed the first phase I clinical trial subjects of the first drug.
-
J Gastroenterol: Multi-target small molecule tyrosine kinase inhibitor Cabotinib is effective in treating advanced liver cancer
Time of Update: 2021-01-15
secondary endpoints include PFS, Total Lifetime (OS), Objective Mitigation Rate (ORR, Full/Partial Mitigation Best Response), Disease Control Rate (DCR, Objective Mitigation or Disease Stability), and Safety.
-
The first domestic research and development of a new generation of NTRK/ROS1 multi-kinase inhibitors project completed Phase I clinical
Time of Update: 2021-01-15
The first domestic research and development of a new generation of NTRK/ROS1 multi-kinase inhibitor SIM1803-1A tablets in China on January 5, 2021 completed the first phase I clinical trial subjects of the first drug.
-
Genome-wide correlation analysis found that acetic kinases and peptide enzymes were hydrolyzed with the Swiss Lactobacillus protein
Time of Update: 2021-01-12
。 Original title: Whole Genome Association Analysis Finds Acetic Kinase and Peptide Enzymes Linked to Swiss Lactobacillus Protein Hydrolysis Capacity Recently, the Key Laboratory of the Ministry of Dairy
-
A new type of primary myoprotein-like subject kinase inhibitor has been developed
Time of Update: 2021-01-05
recently, Liu Qingsong and Liu Jing Pharmaceuticals, researchers at the Institute of Health and Medical Technology of the Hefei Institute of Physical Sciences in China, developed a new type of primary muscle -subject kinase (TRK
